Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent International and Les Laboratoires Servier have signed antibody collaboration on an oncology target involved in tumour cell metabolism provided by Servier.
Subscribe to our email newsletter
As per the agreement Servier will engage BioInvent to screen its proprietary n-CoDeR library for antibodies specific to the undisclosed target.
Servier will also have access to BioInvent’s in-house pre-clinical capacities in selecting an antibody candidate for development.
BioInvent will receive a licensing fee, research support and potential milestone payments of more than EUR11m, as well as royalty on future sales of the product.
Servier R&D president Emmanuel Canet said they will reinforce capacity of using biologics to address cancer targets and look forward to benefit from Bioinvent’s experience in the field.